Byvalson (nebivolol and valsartan), it is an FDA approved drug, approved in June 2016. it is a fixed-dose combination of nebivolol a beta-adrenergic receptor blocker drug, and valsartan is an angiotensin II receptor blocker.
It is mainly used for the treatment of hypertension,
Dosage pattern of byvalson:
It is supplied orally
Initial dose: valsartan 80mg and nebivolol 10mg, the recommended dose is 5mg/80mg to be taken orally once a day
Byvalson Side effects:
The adverse effects are associated with the use of byvalson may include:
- Renal failure
- Skull hypoplasia
It comes in a black box warning of the fetal toxicity. When pregnancy is detected immediately discontinue byvalson as soon as possible.
Mechanism of action:
Nebivolol is a beta-adrenergic receptor blocker and valsartan Is an angiotensin II receptor blocker that blocks that bind of angiotensin II to the receptor in many tissues, such as vascular smooth muscle and adrenal gland, thereby blocking its vasoconstrictor activity and aldosterone-secreting effects.
When the pregnancy is detected, discontinue the drug as soon as possible.
Drugs that directly on the renin-angiotensin system, can cause injury and death of the developing fetus.
It is not to be used if the patient having following conditions such as
- Heart block
- Severe bradycardia
- Cardiac failure
- Sinus syndrome
- Severe hepatic impairment
it is used to treat hypertension, to lower the blood pressure. It is used to alone or along with the other hypertensive agents. Lowering of the blood pressure reduces the risk factors related to the cardiovascular events such as primarily strokes and myocardial infarction. These benefits have been controlled antihypertensive drugs from the wide variety of the pharmacological classes, including beta blockers principally nebivolol belongs to the angiotensin II receptor blocker.
These drugs act on the renin-angiotensin system during the second and third trimester of pregnancy reduces fetal and neonatal morbidity and death. Potential neonates adverse effects include skull hypoplasia, hypotension, renal failure, and death.
Onzetra xsail (sumatriptan nasal powder),
it is an FDA approved drug, approved in January 2016.
Information about onzetra xsail is a serotonin 5-HT1B/1D receptor agonist. It is mainly used to treat a migraine in individuals. It is supplied as a powder for intranasal administration. Delivered with the Xsail powdered delivery device only. The recommended dose is 22mg. the maximum dose in 24hrs period should not exceed two doses separated by at least 2 hrs.
Onzetra xsail Side effects:
Adverse effects associated with this drug are
- Nasal discomfort
- Abnormal taste
Onzetra xsail Mechanism of action:
It is a nasal powder formulation of sumatriptan, it can be bind with cloned 5-HT1B/1D receptors which results in cranial vessels constriction and inhibition of pro-inflammatory neuropeptide release.